ABT - Abbott Laboratories Stock Analysis
Abbott Laboratories (ABT) is a publicly traded company listed on the NYSE. It operates in the Medical Devices industry, part of the broader Healthcare sector. The company has a market capitalization of 211.73B, generates annual revenue of 43.84B, and reports net income of 13.89B. As of the latest data, the stock is trading at 121.76 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. The stock offers a moderate dividend yield (1.96%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.97), indicating current market sentiment. Institutional ownership is reported at 80.62%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 9.59%, trading within a 52-week range of 111.02 - 141.23.
ABT - Abbott Laboratories
121.76
Analyst Consensus
Hold 3.97
ABT – Analyst Rating Summary
- Strong Buy: 10
- Buy: 14
- Hold: 11
- Sell: 0
- Strong Sell: 0
- Total Analysts: 35
| Index: | S&P 500 | P/E: | 15.27 | EPS (ttm): | 7.97 | Insider Own: | 0.67% | Shs Outstand: | 1.74B | Perf Week: | -3.30% |
| Market Cap: | 211.73B | Forward P/E: | 21.47 | EPS next Y: | 5.67 | Insider Trans: | -0.06% | Shs Float: | 1.73B | Perf Month: | -4.02% |
| Income(ttm): | 13.89B | PEG: | 2.08 | EPS next Q: | 1.50 | Inst Own: | 80.62% | Short Float: | 1.01% | Perf Quarter: | -4.60% |
| Revenue(ttm): | 43.84B | P/S: | 4.83 | EPS this Y: | 10.32% | Inst Trans: | 0.32% | Short Ratio: | 2.84 | Perf Half Y: | -1.54% |
| Book/sh: | 29.30 | P/B: | 4.16 | EPS next Y: | 10.07% | ROA: | 17.53% | Short Interest: | 17.40M | Perf Year: | 9.59% |
| Cash/sh: | 4.45 | P/C: | 27.38 | EPS next 5Y: | 10.33% | ROE: | 30.62% | 52W Range: | 111.02 - 141.23 | Perf YTD: | -2.82% |
| Dividend Est.: | 2.39 (1.96%) | P/FCF: | 30.61 | EPS past 3/5Y: | 24.73% 29.98% | ROIC: | 22.21% | 52W High: | 141.23 -13.79% | Beta: | 0.75 |
| Dividend TTM: | 2.40 (1.97%) | Quick Ratio: | 1.24 | Sales past 3/5Y: | -0.88% 5.63% | Gross Margin: | 52.09% | 52W Low: | 111.02 9.67% | Perf 5Y: | 9.85% |
| Dividend Ex-Date: | Jan 15, 2026 | Current Ratio: | 1.70 | EPS Y/Y TTM: | 142.39% | Oper. Margin: | 18.05% | RSI (14): | 36.96 | Volatility: | 1.81% 1.63% |
| Employees: | 114000 | Debt/Eq: | 0.25 | Sales Y/Y TTM: | 6.37% | Profit Margin: | 31.69% | Recom: | 1.77 | Target Price: | 145.71 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.23 | EPS Q/Q: | -2.54% | Payout: | 29.33% | Rel Volume: | 1.68 | Prev Close: | 123.53 |
| Sales Surprise: | -0.18% | EPS Surprise: | -0.21% | Sales Q/Q: | 6.90% | Earnings: | Jan 22 BMO | Avg Volume: | 6.13M | Price: | 121.76 |
| SMA20: | -2.69% | SMA50: | -3.33% | SMA200: | -6.25% | Undervalued: 19.67% | Volume: | 10,287,200 | Change: | -1.43% | |
Graham Classic formula value: 208.69
(P/E=8 * 1g) Min value: 131.18
(current P/E * 2g) Max value: 257.14
Average value: 199.0
About Abbott Laboratories
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.